rs2078267 — SLC22A11

Intronic variant in the OAT4 renal urate transporter that modulates uric acid reabsorption in the proximal tubule, with the C allele raising serum urate and increasing gout risk especially in diuretic users

See your personal result for SLC22A11

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SLC22A11 rs2078267 — A Renal Urate Transporter Variant That Tips the Balance Toward Hyperuricemia

The kidney handles roughly 70% of daily uric acid elimination, and a network of transporters on the proximal tubule determines how much urate is reabsorbed back into the blood versus excreted into the urine. OAT4 (organic anion transporter 4)11 OAT4 (organic anion transporter 4)
Encoded by SLC22A11, OAT4 sits on the apical (urine-facing) membrane of proximal tubule cells and exchanges urate for dicarboxylates like α-ketoglutarate is one of these gatekeepers — a lower-affinity but physiologically important urate reabsorber that works alongside the dominant transporter URAT1 (SLC22A12). The rs2078267 variant lies in an intron of SLC22A11 and is associated with altered OAT4 expression or function, with the C allele linked to higher serum urate concentrations and increased gout risk. This is the third major renal urate locus in GeneOps alongside ABCG2 Q141K (rs2231142)22 ABCG2 Q141K (rs2231142)
A secretory transporter on the gut and kidney that exports urate; the T allele reduces function by 53% and SLC2A9 Arg265His (rs3733591)33 SLC2A9 Arg265His (rs3733591)
GLUT9, the dominant basolateral urate reabsorber in the proximal tubule, and each contributes independently to serum uric acid variance.

The Mechanism

OAT4 is a urate/dicarboxylate exchanger44 urate/dicarboxylate exchanger
It swaps intracellular dicarboxylates (α-ketoglutarate, succinate) for luminal urate, pulling uric acid from the tubular fluid back into the cell expressed on the apical membrane of proximal tubule epithelial cells. While URAT1 (SLC22A12) handles the majority of urate reabsorption with higher affinity, OAT4 provides a parallel reabsorption pathway and also serves as an exit route for loop and thiazide diuretics into the tubular lumen — exchanging the diuretic molecule for urate in the process. This dual role is clinically significant: when diuretics are present, OAT4 activity increases urate reabsorption as a byproduct of diuretic secretion, explaining why thiazide and loop diuretics are well-known triggers of hyperuricemia and gout flares.

The rs2078267 variant is intronic (NM_018484.4:c.1059-957C>T), meaning it does not change the OAT4 protein sequence directly. Instead, the C allele likely enhances OAT4 expression or regulatory activity, increasing net urate reabsorption. In the landmark Global Urate Genetics Consortium (GUGC) meta-analysis55 Global Urate Genetics Consortium (GUGC) meta-analysis
Köttgen et al. analyzed >140,000 individuals of European descent and identified 28 genome-wide significant urate loci, SLC22A11 was one of the ten replicated transporter loci, with the T allele associated with reduced serum urate (β = −0.073, p = 9.4 × 10⁻³⁸). In the ARIC study cohort66 ARIC study cohort
McAdams-DeMarco et al. quantified the per-allele effect at 6.8 µmol/L (~0.11 mg/dL) higher serum urate per copy of the C allele.

The Evidence

The association between rs2078267 and serum urate is one of the most robustly replicated findings in urate genetics. The Köttgen 2013 GUGC study77 Köttgen 2013 GUGC study
Köttgen A, et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet. 2013;45(2):145-54 established SLC22A11 as a genome-wide significant locus in >140,000 Europeans (p = 9.4 × 10⁻³⁸), with the 28 replicated loci collectively explaining 7.0% of serum urate variance. The C allele raises serum urate by approximately 6.8 µmol/L (0.11 mg/dL) per copy in an additive fashion.

A critical finding came from the ARIC gene-by-diuretic study88 ARIC gene-by-diuretic study
McAdams-DeMarco MA, et al. A urate gene-by-diuretic interaction and gout risk. Arthritis Rheumatol. 2015;67(8):2201-9, which demonstrated a significant interaction between rs2078267 and diuretic use (p = 0.010). Individuals homozygous for the C allele who also took thiazide or loop diuretics had substantially elevated gout incidence, consistent with the molecular mechanism: diuretics compete for OAT4 transport, driving increased urate reabsorption as a side effect of diuretic secretion.

Cross-ancestry replication has been robust. An Indian GWAS99 Indian GWAS
Giri AK, et al. Genome wide association study of uric acid in Indian population. Sci Rep. 2016;6:21440 confirmed the association at genome-wide significance in 4,834 individuals (p = 3.26 × 10⁻¹¹) with a larger effect size than in Europeans (β = −10.54 µmol/L for the protective allele). A New Zealand multi-ancestry study1010 New Zealand multi-ancestry study
Hollis-Moffatt JE, et al. Association analysis of SLC22A11 and SLC22A12 with gout in New Zealand. Arthritis Res Ther. 2014;16:R75 found the C allele conferred gout risk in Polynesians (OR 1.51) but not in local Europeans, suggesting ancestry-specific modifier effects.

The C allele frequency varies dramatically by ancestry — near-fixed in East Asians (~98%) and very common in Africans (~85%), moderate in South Asians (~59%) and Latinos (~76%), and lowest in Europeans (~47%). This means the variant contributes most to population-level urate variance in Europeans, where both genotypes are common enough to drive measurable differences.

Practical Actions

The clinical significance of this variant is most pronounced in two scenarios: baseline gout risk assessment and medication selection for hypertension. If you carry two copies of the C allele (CC genotype), your renal urate clearance is genetically reduced, making you more susceptible to hyperuricemia — especially if you also carry risk alleles in ABCG2 (rs2231142) or SLC2A9 (rs3733591). The gene-by-diuretic interaction is clinically actionable: CC carriers prescribed thiazide or loop diuretics for hypertension should have their uric acid levels monitored, and alternative antihypertensives (ACE inhibitors, ARBs, or calcium channel blockers) may be preferable if urate is already elevated.

Dietary purine restriction and adequate hydration become more important with this genotype. Tart cherry extract (500–1,000 mg daily) has demonstrated urate-lowering effects in clinical trials and may offer a low-risk complement to lifestyle measures. Vitamin C at 500 mg daily has modest uricosuric effects by competing with urate for renal reabsorption, though the magnitude (~0.5 mg/dL reduction) is smaller than pharmacological options.

Interactions

This variant operates in the same renal urate handling pathway as two other GeneOps variants. ABCG2 Q141K (rs2231142) reduces urate secretion from the gut and kidney — when combined with SLC22A11 CC (increased reabsorption), the net effect is a double hit: less urate exported and more reabsorbed, compounding hyperuricemia risk. SLC2A9 Arg265His (rs3733591) affects GLUT9, the dominant basolateral urate reabsorber — carrying risk alleles at both SLC2A9 and SLC22A11 amplifies the reabsorption side of the equation through two independent transporters.

The diuretic interaction documented for rs2078267 is mechanistically distinct from other urate loci. OAT4 physically transports diuretic molecules, creating a direct pharmacogenomic link that does not exist for ABCG2 or SLC2A9. This makes the SLC22A11 genotype particularly relevant when evaluating diuretic prescriptions.

Genotype Interpretations

What each possible genotype means for this variant.

TT Efficient Urate Excretor Normal

Two copies of the protective T allele — baseline urate reabsorption at this locus

The TT genotype at rs2078267 represents the lowest-reabsorption state for the OAT4 locus. In GWAS data, TT carriers have serum urate approximately 13.6 µmol/L (0.22 mg/dL) lower than CC homozygotes. The T allele is slightly more common than C in Europeans (53% vs 47%), but rare in East Asians (<2%) and uncommon in Africans (~15%).

The diuretic interaction documented for this locus is weakest in TT carriers, meaning thiazide or loop diuretics are less likely to trigger hyperuricemia via the OAT4 mechanism in this genotype compared to CC carriers. However, diuretics raise urate through multiple mechanisms beyond OAT4, so the standard clinical caution still applies.

CT Moderate Urate Reabsorber Intermediate

One copy of the urate-raising C allele — modestly elevated serum uric acid

The CT genotype represents an intermediate state for OAT4-mediated urate reabsorption. Each C allele contributes approximately 6.8 µmol/L (0.11 mg/dL) to serum urate in an additive model, so heterozygotes fall midway between CC and TT carriers. While this per-allele effect is modest, it adds to the cumulative genetic urate score alongside other loci.

The ARIC study's gene-by-diuretic interaction was strongest for CC homozygotes, but CT carriers on diuretics should also be aware of the potential for increased urate reabsorption through the OAT4 exchange mechanism. The clinical threshold for gout risk is around 6.8 mg/dL, so even small additive effects can matter if your baseline is already in the upper-normal range.

CC Increased Urate Reabsorber High

Two copies of the urate-raising C allele — higher serum uric acid and increased gout risk

The CC genotype at rs2078267 represents the highest-reabsorption state for the OAT4 urate transporter. In the GUGC meta-analysis of >140,000 Europeans, each copy of the C allele raised serum urate by approximately 6.8 µmol/L (0.11 mg/dL), so CC homozygotes carry roughly 13.6 µmol/L (0.22 mg/dL) higher urate than TT homozygotes. While this effect size is modest compared to SLC2A9 or ABCG2 variants, it contributes independently to total genetic urate load.

The ARIC study demonstrated a significant gene-by-diuretic interaction (p=0.010) specifically for this locus: CC carriers on thiazide or loop diuretics had markedly elevated gout incidence compared to other genotypes on the same medications. This interaction has a clear molecular basis — OAT4 exchanges diuretic molecules for urate, so when diuretics are present, CC carriers reabsorb proportionally more uric acid.

The C allele is near-fixed in East Asian (98%) and very common in African (85%) populations, making this variant most discriminating in Europeans (~47%) and South Asians (~59%) where genotype diversity is highest.